RBT 0813
Alternative Names: RBT-0813; TB493-04Latest Information Update: 31 Jan 2022
At a glance
- Originator Twist Biopharma
- Developer Revelar Biotherapeutics; Twist Biopharma
- Class Antivirals; Bispecific antibodies
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 31 Jan 2022 Twist Bioscience enters into a licensing agreement with Revelar Biotherapeutics for the development of RBT 0813
- 05 Jan 2022 Preclinical trials in COVID-2019 infections in USA (Parenteral)
- 05 Jan 2022 Revelar Biotherapeutics plans to submit Investigational New Drug application (IND) in the first half of 2022